Headliner: Dexcom device executive presses connectivity

Headliner: Dexcom device executive presses connectivity

"Some people wake up in the middle of the night worrying about business," Kevin Sayer says. But when he wakes up he can't sleep because he's so excited!

Five things for pharma marketers to know: Friday, March 27

Five things for pharma marketers to know: Friday, March 27

Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system

Editor's Desk—Pill+: Now I'm a Believer

Editor's Desk—Pill+: Now I'm a Believer

If you look at this as simply a tool to drive your brand, you've missed the point

Therapeutic Focus: Respiratory

Therapeutic Focus: Respiratory

The respiratory field, in which several launches are under way, is branching out, from long-time dominant fixed-dose combinations to a therapeutic arsenal that includes biologics and gene therapy. Rebecca Mayer Knutsen investigates the innovation and the intrigue

Diabetes diagnoses jumped as a result of healthcare reform

Diabetes diagnoses jumped as a result of healthcare reform

Diagnoses spiked in states with expanded Medicaid programs. This may mean higher prescription rates, but research shows a lack of diagnoses also has a price.

Shire and Cincinnati Children's Hospital team up in rare diseases

Shire and Cincinnati Children's Hospital team up in rare diseases

The duo hope to begin testing a new treatment within three years.

Researchers say testosterone ads amount to disease mongering

An editorial says the industry's use of terms like "low T" and "andropause" are false and misleading.

Five things for pharma marketers to know: Thursday, March 26

Five things for pharma marketers to know: Thursday, March 26

Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk

Rare Diseases: Target Practice

Rare Diseases: Target Practice

The orphan-drug market was flying high before President Obama announced plans to devote $215 million to the funding of a Precision Medicine Initiative. Imagine the excitement among interested audiences now that those plans have picked up momentum. Frank Celia reports

Physicians call for emphasis on women's health research and care

Physicians call for emphasis on women's health research and care

Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.

Implement a Direct-to-Patient Approach to Increase Patient Engagement and Retention

Implement a Direct-to-Patient Approach to Increase Patient Engagement and Retention

Direct-to-patient approaches can positively impact real world and late phase research programs to increase engagement, retention and data collection.

Bristol-Myers Squibb licenses autoimmune program from Novo Nordisk

The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.

Five things for pharma marketers to know: Wednesday, March 25

Five things for pharma marketers to know: Wednesday, March 25

Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute

DTC Report: DTC Unbound

DTC Report: DTC Unbound

DTC pharma advertising works—ask anyone. But over the years, its effectiveness has been blunted by FDA requirements that, marketers claim, befog rather than clarify. Larry Dobrow surveys the DTC landscape in the wake of the FDA's new—and some say revolutionary—guidance for communicating risk information in print ads

Lawmakers propose allowing pharma companies to share some off-label information

Lawmakers propose allowing pharma companies to share some off-label information

The proposal is part of the 21st Century Cures initiative and would permit drugmakers to provide information about "scientific and medical developments" when communicating with providers and payers.

The New Holistic Approach to Leveraging a Multi-Channel Contact Center

The New Holistic Approach to Leveraging a Multi-Channel Contact Center

Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.

Doctors want specifics on biosimilar labels

An Alliance for Safe Biologic Medicines survey shows what doctors mean by biosimilar transparency.

Five things for pharma marketers to know: Tuesday, March 24

Five things for pharma marketers to know: Tuesday, March 24

Angelina Jolie Pitt discloses she had her fallopian tubes and ovaries removed; the FDA's Zyprexa investigation was inconclusive; Takeda and ImmunoGen sign a $20-million deal

DTC Report: Ten Best DTC Ads of 2014

DTC Report: Ten Best DTC Ads of 2014

Below, a review of last year's 10 best DTC ads, excerpted from MM&M's April cover story, "DTC Report: DTC Unbound," which will be viewable online on Wednesday, March 25. Mary Skoyles reports

Everyday Health buys rare-disease agency Cambridge BioMarketing

Everyday Health buys rare-disease agency Cambridge BioMarketing

The $38-million deal expands the reach of rare-disease campaigns.

Pharma DTC spending jumps almost 21% in 2014

Pharma DTC spending jumps almost 21% in 2014

Nielsen data shows pharma spent $4.5 billion on DTC ads last year.

Opioid deterrence may work, labeling rules are coming

Opioid deterrence may work, labeling rules are coming

A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.

Harrison and Star names co-president

Mario Muredda and Mardene Miller will serve as co-presidents at the healthcare marketing agency.

Baby boomers are no healthier than others

A study shows that greater access to healthcare and lower smoking rates have not made baby boomers healthier than their parents.

Five things for pharma marketers to know: Monday, March 23

Five things for pharma marketers to know: Monday, March 23

Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases

Remembering Warren Ross

Remembering Warren Ross

Warren Ross, the "R" of KPR, passed away a few weeks ago at the age of 88. It isn't easy to sum up a friendship that began more than 50 years ago.

Five things for pharma marketers to know: Friday, March 20

Five things for pharma marketers to know: Friday, March 20

A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik

ASCO wants to talk value when talking cancer

ASCO wants to talk value when talking cancer

An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.

The Patient Abroad: An Exploration of the Motivations and Impact of Medical Tourism

The Patient Abroad: An Exploration of the Motivations and Impact of Medical Tourism

As global healthcare borders become increasingly blurred, the internationally mobile patient may become a standard patient segment considered in healthcare market research.

Sanofi R&D lead takes aim at global drug regulations

The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.

University develops program to turn social media into adverse drug reaction data

A group of computer science and engineering students at the Carlos III Universidad in Madrid used natural language processing techniques to translate social-media and forum posts into adverse drug reaction data.

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

US pharma market value projected to be $550 billion in five years

US pharma market value projected to be $550 billion in five years

Oncology and diabetes medications are expected to be major areas of growth.

What's Your Connected Health Strategy?

What's Your Connected Health Strategy?

At SXSW, for the first time, health wasn't a breakout topic, but rather a "break-in" topic that had the attention of just about every presenter and attendee.

Medtronic teams up with Glooko

The diabetes device manufacturer will soon work with Glooko's platform.

Pfizer takes issue with Little Remedies

The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.

Five things for pharma marketers to know: Wednesday, March 18

Five things for pharma marketers to know: Wednesday, March 18

GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data

23andMe will harness genetic research in new drug discovery unit

23andMe will harness genetic research in new drug discovery unit

The personal genetics company created a therapeutics group to extricate new drug targets from its research database.

Customizing HCP Data In a Challenging Healthcare Environment

Customizing HCP Data In a Challenging Healthcare Environment

Traditional tactics of connecting with physicians are quickly becoming obsolete.

Obesity medications still a hard sell

Increased FDA scrutiny has not garnered trust for the new medications.

Five things for pharma marketers to know: Tuesday, March 17

Five things for pharma marketers to know: Tuesday, March 17

Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing

Apple's ResearchKit: Five Guidelines for Pharma

Apple's ResearchKit: Five Guidelines for Pharma

"In this fast-moving environment, we believe these five guidelines will help guide your clinical trial team in taking full advantage of this exciting new platform."

PCSK9 drugs show viability, tolerability

PCSK9 drugs show viability, tolerability

Amgen and Sanofi/Regeneron shared clinical trial data that shows PCSK9 inhibitors dropped LDL levels by around 60%.

FDA approves Boston Scientific atrial fibrillation device

The approval follows three advisory panel reviews and a complete response letter.

Five things for pharma marketers to know: Monday, March 16

Five things for pharma marketers to know: Monday, March 16

New data suggest Amgen's PCSK9 may reduce risks of heart attacks, Salix bidding is war too rich for Endo's blood, Actavis bipolar drug use is expanded to 10- to 17-year-olds.

Five things for pharma marketers to know: Friday, March 13

Five things for pharma marketers to know: Friday, March 13

J&J sues GlaxoSmithKline over Flonase ads, CDC report finds patients with invasive cancer are living for five years or longer have diagnosis, and Bristol-Myers Squibb resubmits its HCV treatment.

Biosimilar uptake will require companies to tell a trustworthy backstory

Biosimilar uptake will require companies to tell a trustworthy backstory

Reactions to the first biosimilar approval show that marketing and education will be essential for the new category to take market share.

Data on investigational cholesterol-lowering meds to be presented at cardiology meeting

The research will be released as pharmacy benefit managers raise concerns about the potential costs of PCSK9 inhibitors.

CVS exec: biosimilars could discount expensive meds by 40% to 50%

The CMO of CVS Health said biosimilars could drive down prices 10% to 20% lower than current investor expectations.

Five things for pharma marketers to know: Thursday, March 12

Five things for pharma marketers to know: Thursday, March 12

The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.

Endo makes better offer for Salix

Endo makes better offer for Salix

The company argues its offer for Salix is superior to the terms offered by serial acquirer Valeant.

The Next Disruptor of Clinical Trials? Try Apple

The Next Disruptor of Clinical Trials? Try Apple

Apple now offers a way for researchers and developers to easily create clinical trial data-collection apps, revolutionizing the way that patients can participate in clinical trials.

Open Payments glitches limit submissions

Open Payments glitches limit submissions

The CMS said the issues should be resolved this week and will not affect this month's deadline for companies to submit payment data from 2014.

Top insurance lobby backs New York AG in Actavis antitrust case

America's Health Insurance Plans offered its opinion of the Actavis Namenda IR antitrust case, giving its support to New York Attorney General Eric Schneiderman.

AstraZeneca, Joslin Diabetes Center ink three-year collaboration

The partners will focus on developing treatments for metabolic disorders.

Five things for pharma marketers to know: Wednesday, March 11

Five things for pharma marketers to know: Wednesday, March 11

Zogenix spins off painkiller business; Biogen Idec investigates the use of wearables in MS patients; J&J sues Celltrion and Hospira to delay Remicade biosimilar.

Read the complete MM&M Digital Guide 2015

Read the complete MM&M Digital Guide 2015

Click the link below to access MM&M's Digital Guide 2015, with all text, charts and pictures.

Report: US drug spending jumped 13% in 2014

Report: US drug spending jumped 13% in 2014

PBM Express Scripts said last year's trends reflect a major shift in how the pharmaceutical industry does business and that generics are not the bargain they once were.

FDA letter focuses on UCLA claims about an unapproved diagnostic

The agency's Office of Prescription Drug Promotion said a website indicated safety and effectiveness of a diagnostic tool that has not been approved by the FDA.

Collaboration forms to fight misinformation in genetic testing

A recent analysis found that most websites touting personal cancer medicine failed to provide risk data, while an insurer and a health system team up to develop best practices to improve the "how" of genetic testing.

Survey suggests doctors increasingly look for digital engagement

A new survey from Cegedim Relationship Management claims that digital tools are being underutilized and represent an opportunity to meet the demands of HCPs.

Five things for pharma marketers to know: Tuesday, March 10

Five things for pharma marketers to know: Tuesday, March 10

HCV drugs and other specialty medications drove a 13% increase in last year's prescription spending, the CBO overestimated just how much healthcare reform would cost, and an FDA panel voted 17-0 in favor of Kythera's drug that can reduce double chins.

Evolving views of obesity raise questions about the role of weight-loss drugs

Evolving views of obesity raise questions about the role of weight-loss drugs

Doctors tell MM&M that prescription weight-loss medications are just one component of an obesity treatment regimen.

FDA releases new e-informed consent guidance in bid for more efficient trials

FDA releases new e-informed consent guidance in bid for more efficient trials

The agency hopes the adoption of electronic informed consent measures could help participants retain and understand information as well as allow quicker timing of updates.

Apple launches software platform for medical research

The open-source framework uses the iPhone's apps to gather users' health information.

Five things for pharma marketers to know: Monday, March 9

Five things for pharma marketers to know: Monday, March 9

Novartis CEO says cost cutting is looming; Novo Nordisk presents new Saxenda weight-loss data; FDA approves Astellas Pharma's antifungal drug.

Read the complete March 2015 Digital Edition

Read the complete March 2015 Digital Edition

Click the above link to access the Digital Edition of the March 2015 issue of MM&M, with all text, charts and pictures.

FDA hands Amgen a biosimilar competitor

FDA hands Amgen a biosimilar competitor

The regulator approved Novartis's Neupogen lookalike. Amgen, which markets Neupogen, has a trove of its own potential biosimilars.

The Future of Commercial in a Global Multichannel Marketplace

The Future of Commercial in a Global Multichannel Marketplace

Five things for pharma marketers to know: Friday, March 6

Five things for pharma marketers to know: Friday, March 6

FDA approves the first biosimilar, judge rules that FDA panel members had conflicts of interest, and a new venture will evaluate the effectiveness of digital health technologies.

Imbruvica eases AbbVie's patent worries

Imbruvica eases AbbVie's patent worries

AbbVie's $21-billion bid to acquire Pharmacyclics may insulate the drugmaker from the impact of impending Humira biosimilars.

Tufts: biosimilars will not be an instant hit

A study by the nonprofit research group found resistance to drug switching.

Accenture survey finds lacking alignment between pharma IT and marketing

The move toward digital will likely bring greater collaboration between CMOs and CIOs.

Eisai and Merck make cancer research pact

The drugmakers will explore combinations of Merck's Keytruda and Eisai's Lenvima and Halaven to treat certain cancers.

Five things for pharma marketers to know: Thursday, March 5

Five things for pharma marketers to know: Thursday, March 5

AbbVie nabs Pharmacyclics for $21 billion, Mallinckrodt makes a Pfizer-Hospira style acquisition, and the National Cancer Institute's director resigns

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

The FDA granted the drug Priority Review status just last week.

HCB Health acquires Topin & Associates

HCB Health acquires Topin & Associates

Austin-based HCB Health announced Tuesday its acquisition of Chicago indie agency Topin & Associates in an effort to push the borders of its client base.

Orexigen pleases shareholders, irks FDA

The drugmaker released interim clinical trial information in an SEC filing that the FDA wanted kept quiet until the trial was completed.

Haymarket Media acquires digital agency Group DCA

Haymarket Media acquires digital agency Group DCA

Haymarket purchased HCP-engagement specialist Group DCA and will operate the digital agency out of its custom medical communications division.

Five things for pharma marketers to know: Wednesday, March 4

Five things for pharma marketers to know: Wednesday, March 4

FDA adds new language to low-T drug labels; Afrezza's launch has a poor start, investors say; BMS acquires prostate-cancer vaccine in a deal worth $975 million.

Researchers find safety disclaimers do not register with consumers

The study indicates patients discount wording that indicates the FDA has not approved supplement claims.

Safety advocate, DOJ settle kickback allegations

The agreement includes a $1-million payment.

IPG merges ICC Lowe shops into FCB Health, amid sluggish digital growth

IPG merges ICC Lowe shops into FCB Health, amid sluggish digital growth

Holding company will now focus on two health networks—FCB Health and McCann Health

Digital Partners 2015

Digital Partners 2015

Think Tank: There's Work to Do

Five digital pharma experts benchmark the industry's progress and project the next big digital trends

Consumers: Patients and Virtues

Consumers: Patients and Virtues

Consumers come with the same basic set of instructions as HCPs—find out what they need, then offer meaningful solutions. But be warned: Shiny objects may cause a temporary loss of vision

Healthcare Professionals: Chaos Breeds Opportunity

Healthcare Professionals: Chaos Breeds Opportunity

Increasingly pressed for time, the last thing physicians need is more engagement opportunities with pharma, right? Wrong. It's all about offering the right content in the right format at the right time

Overview: Can't, Won't, Don't Stop

Overview: Can't, Won't, Don't Stop

As pharma continues to scale the digital curve, James Chase's assessment of the landscape paints a familiar picture of progress and encouragement mixed with frustration and pain

Five things for pharma marketers to know: Tuesday March 3

Five things for pharma marketers to know: Tuesday March 3

NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.

Amgen results for Kyprolis could sideline Velcade

Amgen results for Kyprolis could sideline Velcade

Analysts say head-to-head study results could make Kyprolis the lead treatment.

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Drugmakers face increasing pressure on pricing from insurers and PBMs.

Pradaxa antidote goes to FDA

The breakthrough designation therapy drug was the first for its drug class.

GAO: Dementia patients receiving harmful antipsychotics

Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.

Five things for pharma marketers to know: Monday, March 2

Five things for pharma marketers to know: Monday, March 2

Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.

Skill Sets: Cello Health Insight

Skill Sets: Cello Health Insight

A monthly showcase of companies offering expertise, experience and services within specific areas of the industry. In this edition: multichannel marketing

MAHF 2015: An Evening of Icons

MAHF 2015: An Evening of Icons

The industry celebrated its most precious asset—its people—at The Pierre in New York City on February 3 with a dinner honoring the two most recent inductees to the Medical Advertising Hall of Fame and the 2015 "Future Famers"

Five things for pharma marketers to know: Friday, February 27

Five things for pharma marketers to know: Friday, February 27

Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.

How to Win an MM&M Award: 2015

How to Win an MM&M Award: 2015

You have fewer than six weeks to enter the MM&M Awards. No problem. Follow our checklist of Do's and Don'ts and tune in to our webcast on March 24 for more tips.

5 Steps to Successful Key Account Management

5 Steps to Successful Key Account Management

The healthcare ecosystem is changing rapidly to succeed requires the adoption of key account management (KAM), a systematic, robust alternative to the traditional buyer/seller model.

Viewpoint: Putting analytics into commercial strategy

Viewpoint: Putting analytics into commercial strategy

Sales reps, supported by rich customer data, will become relationship managers

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters